Carfilzomib, Iberdomide, and Dexamethasone (KID) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Results from a Phase 1/2 Study (IMS 2026) - Sep 11, 2026 - Abstract #PA-063; Pres time: Sep 24, 2026; P1/2 | "Introduction: Standard upfront regimens demonstrate stringent complete response (sCR) rates of 10-15% following induction, and 40% following consolidation in patients (pts) with newly diagnosed multiple myeloma (NDMM). Induction tx with KID achieved 31% sCR/CR rates post ASCT overall and 31% in the high-risk NDMM pts at interim analysis, despite short tx duration. All pts were successfully mobilized. Further studies will evaluate KID with post-ASCT iber + elranatamab consolidation followed by iber maintenance."
Clinical • P1/2 data • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Targeted Protein Degradation • Thrombocytopenia • Transplantation • CRBN
|
|
Noa Biran1; James Di Palma-Grisi1; Patrick C. Roney2; Kimberley Doucette2; David H. Vesole1; Harsh V. Parmar1; Pooja Phull1; Bianca DeAgresta3; Jaeil Ahn2; Rena Feinman4; Joshua Zenreich3; Palka Anand3; Lisa Biamonte3; Monique Pace3; Alexandra Hampson3; Adolfo Aleman3; Ella Rutanen2; Genevieve Breeze3; Aimee Chappell2; Susan Kumka3; David S. Siegel3
|